Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China (GATE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Rui Huang, M.D., Ph.D
- Phone Number: 20201 +86-25-83106666
- Email: doctor_hr@126.com
Study Contact Backup
- Name: Chao Wu, M.D., Ph.D
- Phone Number: +86-25-83105890
- Email: dr.wu@nju.edu.cn
Study Locations
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213001
- The Third People's Hospital Of Changzhou
-
Huai'an, Jiangsu, China, 223300
- Huai'an No.4 People's Hospital
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
-
Suzhou, Jiangsu, China, 215000
- The Affiliated Infectious Diseases Hospital of Soochow University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Positive HBV surface antigen (HBsAg) for 6 months or more;
- Elevated ALT levels (>1×ULN) and detectable HBV DNA;
- Treatment-naïve;
- Willing to attend this study and able to provide the written informed consent.
Exclusion Criteria:
- Co-infection with other viral hepatitis and human immunodeficiency virus;
- Concurrent with other chronic liver diseases, including primary biliary cirrhosis, autoimmune hepatitis, alcoholic hepatitis, nonalcoholic fatty hepatitis, and hereditary metabolic liver disease;
- Patients with liver cirrhosis;
- Coexistence of hepatocellular carcinoma and other malignant tumor;
- Underwent liver transplantation before the enrollment;
- Severe cardiac, renal, respiratory, hematological, or psychiatric illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Integrated intervention strategies
|
Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The proportion of indicated-but-not-treated CHB patients.
Time Frame: 18 months
|
The proportion of indicated-but-not-treated CHB patients.
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The proportion of lost to follow-up in CHB patients.
Time Frame: 18 months
|
18 months
|
|
The frequency of follow-up visit in CHB patients.
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IN-CN-320-6104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.